Characterization and vaccine-induced immunogenicity of a re-emerging Neisseria meningitidis serogroup Y in Tianjin, China

Compared with MPSV4, MCV4 generated stronger bactericidal antibody responses and provided superior protective immunity against serogroup Y in a mouse model, which lays the groundwork for further development of meningococcal vaccines. Moving forward, studies should incorporate a broader range of bacterial strains, larger sample sizes, and ultimately human clinical trials to confirm and extend these findings.